Big pharma, Partnering, Pharma

Boehringer Ingelheim and Oxford BioTherapeutics in oncology pact

Posted on 15 January 2015

Tags: , , ,

Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration.

The target was discovered using Oxford BioTherapeutics' proprietary OGAP system, which incorporates one of the world's largest proprietary proteomic databases, integrating clinical, experimental and expression data.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


This represents the first option exercised under the companies' oncology target discovery and validation collaboration established in 2013.

Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply